Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03122938
Other study ID # RD02914009A
Secondary ID
Status Enrolling by invitation
Phase N/A
First received August 20, 2016
Last updated April 20, 2017
Start date April 2016
Est. completion date May 2017

Study information

Verified date April 2017
Source Beingmate Baby & Child Food Co Ltd .
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the effects of a lactoferrin supplemented formula on fetal development , iron metabolism and immunity in healthy pregnant women. One hundred and twenty healthy pregnant women (24<gestational weeks<26) are enrolled and randomly assigned to lactoferrin-supplemented formula group (active group) or normal formula group (control group, without lactoferrin supplementation). Subjects allocated in active group consume lactoferrin supplemented formula (85mg lactoferrin per 100g) 3 times a day (81g totally), while those in control group consume formula without lactoferrin supplementation (<6mg lactoferrin per 100g formula) according to the same schedule. Routine blood test including hemoglobin and serum ferritin, and food frequency questionnaire-based review and 24h*3 dietary record are performed every 4 weeks during intervention until delivery. Body weight of newborns are recorded after delivery. The differences in iron deficiency anemia morbility of pregnant women and anthropometric measurements of newborns between groups would be analyzed after completion of this study.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 120
Est. completion date May 2017
Est. primary completion date April 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 34 Years
Eligibility Inclusion Criteria:

- healthy pregnant women with gestational weeks between 24 and 26;

- with hemoglobin concentration > 110g / L;

- without indication of abortion;

- without infectious disease or hereditary disease;

- without iron supplementation before enrollment.

Exclusion Criteria:

- with red blood count <3.5*10^12/L,hemoglobin concentration<110g/L or serum ferritin <20 µg/L;

- diagnosed with gestational diabetes mellitus;

- enrolled in other intervention study within past 1 month.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
lactoferrin-supplemented formula
Subjects consume lactoferrin-supplemented formula (85mg lactoferrin per 100g) 3 times a day (81g totally).
formula without lactoferrin supplementation
Subjects consume formula without lactoferrin supplementation (<6mg lactoferrin per 100g formula) 3 times a day (81g totally).

Locations

Country Name City State
China Sir Run Run Hospital Hangzhou Zhejiang

Sponsors (2)

Lead Sponsor Collaborator
Beingmate Baby & Child Food Co Ltd . Sir Run Run Shaw Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary iron-deficiency anemia morbility of pregnant women every 4 weeks during intervention, namely 28th gestational weeks, 32nd gestational weeks, 36th gestational weeks and the day of delivery.
Secondary iron metabolism of pregnant women hemoglobin concentration and serum ferritin concentration every 4 weeks during intervention, namely 28th gestational weeks, 32nd gestational weeks, 36th gestational weeks and the day of delivery.
Secondary fetal growth body weight of newborns the day of delivery, recorded by nurse.
Secondary fetal growth and development body length of newborns the day of delivery,recorded by nurse immediately
Secondary fetal development head circumference the day of delivery, measured and recorded by nurse.
See also
  Status Clinical Trial Phase
Completed NCT04949165 - Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study N/A
Active, not recruiting NCT02541708 - IV Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania Phase 3
Completed NCT01942460 - Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients Phase 4
Completed NCT00810030 - FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR Phase 3
Completed NCT01047098 - Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation N/A
Completed NCT00298051 - Umbilical Cord Clamping and Infant Iron Status N/A
Completed NCT01135576 - Iron Fortified Beverages and Application in Women Predisposed to Anemia N/A
Withdrawn NCT04320966 - Neurovascular Complications and White Matter Damage in Acquired Anemias
Completed NCT01101399 - Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy Phase 3
Completed NCT05240677 - Endoscopy in CKD With Iron Deficiency Anemia N/A
Terminated NCT01100879 - Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy Phase 4
Recruiting NCT02487719 - Different Iron Supplements for Prevention of Anemia in Pregnancy Phase 4
Recruiting NCT03232554 - Buxue Yimu Pills for Gynecological Iron-Deficiency Anemia Phase 2
Terminated NCT02341300 - Use of Cast Iron Pots to Improve Maternal Anemia N/A
Completed NCT04318405 - Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).
Completed NCT02998697 - Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia Phase 2/Phase 3
Not yet recruiting NCT03411590 - The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers N/A
Completed NCT05365308 - EHR-based Patient Identification and Panel Management of Patients With Iron Deficiency Anemia N/A
Recruiting NCT01071759 - Effects of Dietary Heme/Non-heme Iron and Helicobacter Pylori (Hp) Infection on Maternal Iron-deficiency Anemia and Fetal Growth Outcomes N/A
Terminated NCT00882414 - Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD) Phase 2